Clinical Trials Arena May 27, 2025
GlobalData

Cell and gene therapy is poised to revolutionize the treatment of complex diseases, offering new possibilities for patients. However, for the industry to fulfill its immense promise, the market must develop in parallel to address the significant cost of products.

Cell and gene therapy (C&GT) represents a major advance in medical treatments by directly targeting the root causes of diseases at the cellular or genetic level, rather than managing the symptoms. Treatments offer significant promise for many patients living with severe and often life-threatening conditions. If administered as first-line therapies, cell and gene products have the potential to significantly improve patient outcomes more effectively than traditional treatments, leading to better disease management, reduced symptoms, and in some cases, even a...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
What’s new with GLP-1s
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable

Share Article